A Phase 1b Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of ABBV-382 in Persons Living with HIV-1 (PLWH)

Infectious Diseases

This study is being conducted to evaluate the safety and tolerability of ABBV-382 in persons living with HIV-1 on combination antiretroviral therapy.

More information regarding this study can be found: https://clinicaltrials.gov/ct2/show/NCT04554966

Sponsor(s)
Abbvie
Principal Investigator(s)
Dr. Jose Lucar, MD/Infectious Diseases
Contact Phone Number
(202) 741-2442
Request Information
CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.